The FDA and CMS Just Launched a New Breakthrough Device Coverage Pathway. Here’s What It Actually Covers.

For years, one of medtech’s most persistent frustrations has been the gap between FDA authorization and Medicare coverage. A device can clear the FDA’s most rigorous review, demonstrate clinical efficacy in a pivotal trial, and still wait a year or more — sometimes much longer — before CMS issues a National Coverage Determination. According to a 2022 survey from the Stanford Byers Center for Biodesign and the Duke-Margolis Center for Health Policy, the average time from FDA authorization to national Medicare and commercial coverage is five years.

On April 23rd, CMS and FDA announced a new attempt to close that gap. The Regulatory Alignment for Predictable and Immediate Device coverage pathway — RAPID — is designed to bring the two agencies into alignment earlier in the development process, so that evidence generated for FDA review can also satisfy Medicare coverage requirements. Under the pathway, CMS would issue a proposed NCD the same day an eligible device receives FDA marketing authorization. The 30-day public comment period would follow, and national coverage could take effect as soon as two months after authorization — down from a year or more today.

The agencies have tried versions of this before. The FDA’s Parallel Review Program launched as a pilot in 2011 and was fully implemented in 2016; as of late 2024, 97 devices had requested participation, and two had completed it. The first Trump administration’s MCIT rule offered four years of automatic Medicare coverage upon FDA authorization, but was scrapped by the Biden administration, which replaced it with the Transitional Coverage for Emerging Technologies pathway in 2024. TCET was capped at 5 devices per year, even though the FDA typically grants more than 100 breakthrough designations in that time. AdvaMed criticized TCET for exactly that reason. TCET is now paused as CMS shifts focus to RAPID.

The Eligibility Gap

This is where the announcement warrants careful reading. RAPID is not available to all breakthrough devices. Class III breakthrough devices qualify regardless of additional program participation. Class II breakthrough devices qualify only if they are enrolled in FDA’s Total Product Life Cycle Advisory Program, or TAP — an enhanced engagement program initiated under MDUFA V. All eligible devices must also be the subject of an Investigational Device Exemption study that enrolls Medicare beneficiaries and studies clinical outcomes agreed upon by both agencies. That IDE requirement alone excludes non-significant risk devices, which make up the majority of the Class II market.

A senior CMS official said on the day of the announcement that approximately 40 devices currently qualify, with another 20 potentially eligible. For context: as of December 30, 2025, FDA had granted 1,246 Breakthrough Device Designations, with 185 devices having received marketing authorization. More than 1,000 breakthrough-designated devices remain outside the pathway’s reach under the same coverage dynamics as before. As Jennifer Newberger of Hyman, Phelps & McNamara wrote in a post-announcement analysis, RAPID may function as “less a systemic solution than a targeted pilot for a narrow slice of the market.”

Industry Response and What to Watch

AdvaMed called RAPID a “positive step” but stopped short of an endorsement, with CEO Scott Whitaker noting that “without meaningful timelines, accountability, and effective management of this program, patients are unlikely to see the full benefits of new technologies.” Whitaker also flagged a complicating factor: CMS has separately proposed repealing the New Technology Add-on Payment alternative pathway for breakthrough devices, which provides temporary reimbursement supplements to hospitals offering procedures with newly authorized technologies. NTAP and RAPID serve different but complementary roles in the access equation, and industry is watching both simultaneously.

The proposed procedural notice will be published in the Federal Register, opening a 60-day public comment period. RAPID does not take formal effect until CMS issues a final notice in response to those comments. How the agencies respond to stakeholder input — particularly on whether TAP participation should remain a prerequisite for Class II eligibility — will determine whether RAPID stays narrow or expands its reach. For companies that do qualify, the most immediate implication is practical: trial design conversations with CMS should begin earlier than they have historically, and IDE protocols should be structured with Medicare outcomes in mind from the start.

SPONSORED BY RŌG HEALTH

Most medical device companies don't fail on technology. They fail on sequencing.

The most expensive mistakes in Class II and III device commercialization aren’t made in the field. They’re made before it — launching before buyer clarity exists, fundraising before the story holds up, hiring before positioning is right.

The CLIF Analysis from RŌG Health is a quick, structured external diagnostic that helps you identify gaps before they become costly. One week. Built for medical device and medtech teams.

Learn about the CLIF →

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about sponsorship opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

8 things to watch this week:

1. 🏛️ CMS & FDA Launch RAPID Coverage Pathway for Breakthrough Devices

CMS and FDA jointly unveiled the Regulatory Alignment for Predictable and Immediate Device (RAPID) pathway, which could compress Medicare coverage timelines for breakthrough devices from over a year down to as little as two months. Roughly 40 existing devices qualify immediately — and with permanent Medicare coverage on offer (not the four-year window of prior programs), this fundamentally changes the commercial calculus for companies building toward a breakthrough designation.

FierceHealthcare

2. 🎯 86% of Medtech Teams Make Claims Their Evidence Can’t Back Up

In our Q1 client study, that’s what we found — claims outpacing evidence by enough to create real exposure in investor due diligence, health system reviews, or partner conversations. Most teams don’t see it because nothing breaks until the room actually matters.

We recently worked with a company preparing for a $25M Series A raise. Three weeks out, we found a claims-evidence gap that would have surfaced in due diligence. They fixed it before it cost them.

If you’re heading into a raise, a launch, or a strategic conversation in the next 90 days, take two minutes to see where you stand.

Take the free readiness check →

Sponsored

3. 🤖 Intuitive Surgical Posts Blowout Q1, Raises Full-Year Guidance

Intuitive reported $2.77B in Q1 revenue (+23% YoY), beating consensus by ~5.5%, with EPS of $2.50 crushing estimates by nearly 17%. Da Vinci procedure volume grew 16% and Ion surged 39%. Management raised its full-year procedure growth outlook and shares jumped more than 7% — the clearest signal yet that surgical robotics demand is not slowing down.

Proactive Investors

4.📉 Boston Scientific Slashes 2026 Guidance Despite Solid Q1

BSX posted solid Q1 revenue of $5.2B (+11.6%), but dramatically cut its full-year sales growth forecast from 10.5–11.5% down to 7–8.5%, citing unexpected headwinds in its Farapulse PFA platform, Watchman, and Urology franchises. Competitors Medtronic, J&J MedTech, Abbott, and Kardium are all gaining ground in electrophysiology — and CEO Mike Mahoney called the guide-down something the company was “not proud of.”

MedTech Dive

Before we continue — quick question for you:

Thanks — now back to the news.

5. 💊 Johnson & Johnson MedTech Grows 4.6% in Q1, Raises Full-Year Guidance

J&J’s MedTech segment posted $8.6B in Q1 sales with 4.6% operational growth, driven by cardiovascular, surgery, and vision. The company raised its full-year 2026 operational sales guidance to 5.9–6.9%, targeting $100B+ in total company revenue — and its OTTAVA robotic surgery system is now a credible threat to Intuitive Surgical in the multi-port segment by late 2026.

Yahoo Finance / GuruFocus

6. 🤝 Stryker Acquires Amplitude Vascular; Avanos Goes Private in Active M&A Week

Stryker announced its acquisition of Amplitude Vascular Systems (IVL-based vascular technology) in a week that also saw Avanos Medical agree to be taken private at a 72% premium. Zooming out: Q1 2026 medtech M&A totaled $26.6B across 37 deals — with deal flow accelerating around surgical robotics, cardiovascular, and diagnostics — signaling that strategic portfolio reshaping remains a defining theme of the year.

FierceBiotech / J.P. Morgan

7. ⚠️ FDA Issues Class I Recall for Tandem Mobi Insulin Pumps Over Software Flaw

The FDA classified a software correction for Tandem’s Mobi insulin pump as a Class I recall — its most serious designation. A false motor detection error can halt insulin delivery entirely, risking severe hyperglycemia. Over 17,700 devices are affected and users are urged to update to software version 7.9.0.2 immediately. This is the latest in a string of diabetes device safety actions from the FDA in 2026, including a prior Insulet Omnipod 5 recall in March.

MedTech Dive / FDA

8.💡 AcuityMD Raises $80M Series C, Valued Near $1B

AcuityMD, the AI commercial intelligence platform used by 16 of the top 20 medtech companies, raised $80M in a Series C led by StepStone Group. The company — which has helped customers identify more than $34B in pipeline opportunities — plans to accelerate agentic AI for sales and marketing teams and expand beyond commercial use cases across the full product lifecycle. With the medtech sector increasingly competing on commercial execution, this signals where the next wave of operational investment is headed.

The AI Insider

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about sponsorship opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

Stereotaxis to buy Robocath for up to $45M

Stereotaxis has agreed to acquire robotic PCI developer Robocath in a deal valued at up to $45 million, adding coronary intervention capabilities to a platform historically focused on electrophysiology.

The transaction includes $20 million upfront and up to $25 million in milestone-based payments tied to regulatory and commercial progress, including FDA clearance of Robocath’s next-generation system. That structure reflects both the strategic intent and the remaining execution risk, particularly in the U.S. market, where Robocath does not yet have approval.

At the product level, the companies bring distinct technologies. Stereotaxis has built its business around magnetic navigation systems used primarily in cardiac ablation — its Synchrony platform, which recently received FDA clearance, and the broader GenesisX and SynX ecosystem give the company proprietary building blocks for the integration ahead. Robocath’s R-One+ platform enables robotic manipulation of guidewires and devices during percutaneous coronary interventions. The system is CE marked and in limited commercial use outside the United States, with 15 systems installed globally. Clinical data from the multicenter R-EVOLUTION study showed 100% clinical success and 95.2% technical success across 62 patients with no complications at 30 days, though the study authors noted that larger populations and more complex lesion profiles will be needed before the evidence base is considered mature.

The rationale for combining those capabilities points to a broader shift in how robotic intervention is developing.

For much of the past decade, systems in this category have been designed around individual procedures, with companies attempting to establish clinical and economic value within narrowly defined use cases. The most established robotic PCI system in the U.S. market — Siemens Healthineers’ CorPath GRX — reflects that approach: a capable, cleared platform that has built its case specifically in interventional cardiology. Stereotaxis is taking a different position. By adding PCI and positioning for eventual expansion into neurovascular intervention, the company is moving toward a multi-procedure platform that can be deployed across service lines rather than anchored in a single specialty.

That strategy reflects a view that the barrier to adoption in robotic intervention is no longer primarily technical. It is structural — tied to workflow integration, physician training, and the ability to support consistent procedural volume.

Whether this acquisition addresses those constraints is less clear.

Integrating magnetic navigation and mechanical robotic control into a unified system presents practical challenges. The technologies operate differently, require different forms of physician interaction, and have been developed for distinct clinical settings. Stereotaxis has existing proprietary hardware and software infrastructure to build from, but bringing them together in a way that simplifies, rather than complicates, use in the cath lab will be critical. The company has projected Robocath will contribute roughly $2 million in revenue in the first year post-acquisition, with breakeven expected by the third year — figures that underscore just how early this integration is in commercial terms, even as the strategic logic is clear.

The regulatory timeline adds another layer of uncertainty. Robocath’s current platform is not approved in the U.S., and future clearance is already embedded in the deal’s economics. Stereotaxis has indicated it plans to pursue regulatory submissions in both the U.S. and Europe within two years. Until that milestone is achieved, the platform Stereotaxis is building remains only partially realized in its largest potential market.

The deal ultimately sits within a broader inflection point for robotic intervention in medtech.

Companies are beginning to move away from procedure-specific systems toward platforms that can support a wider range of interventions. The logic is straightforward: broader applicability can support higher utilization, and higher utilization is what justifies adoption. At the same time, expanding platform scope introduces new complexity — in integration, in training, and in demonstrating consistent value across different clinical contexts.

Stereotaxis is effectively placing a bet on which of those forces will dominate.

If a broader platform can translate into more routine use, this type of consolidation could accelerate adoption across interventional cardiology and adjacent fields. If not, the risk is that added capability increases system complexity without materially changing how often these technologies are used.

That dynamic extends beyond a single transaction. It is increasingly central to how the next phase of robotic intervention in medtech will be defined.

SPONSORED BY RŌG HEALTH

86% of Medtech Teams Have Claims Their Evidence Can’t Back Up

In our Q1 client study, that’s what we found — claims outpacing evidence by enough to create real exposure in investor due diligence, health system reviews, or partner conversations. Most teams don’t see it because nothing breaks until the room actually matters.

We recently worked with a company preparing for a $25M Series A raise. Three weeks out, we found a claims-evidence gap that would have surfaced in due diligence. They fixed it before it cost them.

If you’re heading into a raise, a launch, or a strategic conversation in the next 90 days, take two minutes to see where you stand.

Take the free readiness check →

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about sponsorship opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

8 things to watch this week:

1. 🏛️ CMS proposes repeal of add-on payment path for breakthrough devices

CMS is proposing to eliminate a payment pathway that was designed to help breakthrough devices gain traction in the hospital setting. For emerging medtech companies, that raises the stakes on reimbursement planning and could make commercialization even harder for products that already face long adoption cycles.

Healthcare Dive

2. 🎯 86% of Medtech Teams Make Claims Their Evidence Can’t Back Up

In our Q1 client study, that’s what we found — claims outpacing evidence by enough to create real exposure in investor due diligence, health system reviews, or partner conversations. Most teams don’t see it because nothing breaks until the room actually matters.

We recently worked with a company preparing for a $25M Series A raise. Three weeks out, we found a claims-evidence gap that would have surfaced in due diligence. They fixed it before it cost them.

If you're heading into a raise, a launch, or a strategic conversation in the next 90 days, take two minutes to see where you stand.

Take the free readiness check →

3. 💰 Abbott trims 2026 profit forecast on Exact Sciences deal impact

Abbott’s reduced outlook is a reminder that even large strategic transactions can create real near-term pressure before the market rewards the longer-term rationale. For medtech leaders, it’s another signal that portfolio expansion still has to clear the test of integration, margin discipline, and investor confidence.

Reuters

4. 🤝 AIP to acquire Avanos Medical in $1.27B go-private deal

A $1.27 billion take-private deal is the kind of headline that gets attention across the industry, especially as private equity continues to hunt for medtech assets with room for operational improvement. It also reinforces that strategic value in medtech is still being found well beyond the venture-backed startup class.

MedTech Dive

5. 🧠 GE HealthCare, RadNet expand AI mammography collaboration

AI in imaging keeps moving from concept to commercial workflow, and this expanded mammography collaboration is a strong example of where that momentum is showing up. The broader takeaway is that enterprise-scale AI adoption in diagnostics is increasingly being driven by partnerships with clear clinical and operational use cases.

MedTech Dive

6. 📊 FDA and industry close in on MDUFA VI user-fee agreement

The next user-fee agreement will shape review capacity, timelines, and regulatory expectations for years to come, which makes this a closely watched development even if it is less flashy than an acquisition or recall. For device makers, this is one of those policy signals that quietly affects everything from planning assumptions to submission strategy.

MedTech Dive

7. ⚠️ Medline recalls angiographic syringes, receives FDA warning letter

Recalls paired with an FDA warning letter tend to draw attention because they combine immediate operational risk with reputational exposure. Beyond the headline, this is another reminder that quality system weaknesses can quickly become commercial problems, not just regulatory ones.

MedTech Dive

8. 🤖 Stereotaxis to acquire Robocath

Robotic intervention remains one of the more compelling strategic themes in medtech, and this deal gives Stereotaxis a broader footprint in that race. It is a meaningful signal that companies in procedure-driven categories still see platform consolidation as a faster path to relevance than building everything organically.

Endovascular Today

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about sponsorship opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

Luminai Raises $38 million Series B to Scale Intelligence Across Health System Operations

By now, the market has heard a thousand versions of the healthcare AI pitch. Scribes. Copilots. Chatbots. Summarizers. What is getting more interesting now is where capital is actually landing: not at the clinical edge first, but in the operational middle of the system, where referrals, compliance, access, and revenue workflows still run through faxes, PDFs, and fragmented data. That is the real signal inside Luminai’s $38 million Series B.

This is why the Cleveland Clinic angle matters more than the financing headline itself. Luminai’s partnership with the system — one that sees roughly 15 million patients annually — spans access, revenue cycle, compliance, and referrals. But if referral management is where the deployment is taking root first, as reported context suggests, it is telling you something about where the pain is. Referral workflows are high-volume, messy, labor-intensive, and directly tied to patient access. They are also full of exactly the kind of unstructured information traditional software has never handled particularly well.

Luminai’s bet is that healthcare does not need another point solution so much as it needs software that can interpret that mess, structure it, route it, and keep the process moving with human oversight when confidence falls short. In other words, this is not an AI-as-feature story. It is an AI-as-infrastructure story.

That distinction matters because the commercial logic here is unusually strong. Administrative waste in U.S. healthcare is still massive, and the case for attacking it has become much easier to make inside provider organizations under financial pressure. If a company can remove even part of the invisible manual labor that keeps referrals and back-office processes from stalling, the value proposition is immediate.

But this is also where the story gets more interesting — and more complicated — than a standard funding announcement. PHTI’s April 2026 report on administrative AI makes the point bluntly: administrative AI is advancing quickly, especially in areas like prior authorization and billing, but automation layered onto flawed workflows does not automatically reduce system-level costs. Sometimes it just makes every side faster at doing the same bureaucratic dance.

That is the bigger question hanging over this category. Can administrative AI actually simplify healthcare, or is it going to become the next arms race, where providers automate submissions, payers automate reviews, and complexity survives with better response times? Speed is valuable. But speed and simplification are not the same thing.

Luminai may have chosen a smart beachhead. Referrals are politically cleaner than some of the more contentious administrative categories, and the outcomes are easier to see. If intake improves, wait times shorten, staff time gets redeployed, and patient access gets smoother, health systems can feel the result before they have to model the downstream economics. That makes referral management a credible proving ground for the broader thesis.

This is also why the story likely resonated so strongly with your readers. The market has no shortage of AI headlines right now, but relatively few of them are anchored in the hidden operating layer that determines how patients actually move through a health system. For medtech and health-tech leaders, that layer matters more than it gets credit for. It shapes adoption, throughput, staffing strain, and ultimately how fast innovation reaches the point of care.

So the real takeaway this week is not simply that another healthcare AI company got funded. It is that the next meaningful battleground may be operational infrastructure, and buyers are beginning to treat it that way. The question now is not whether health systems want administrative AI. They clearly do. The question is whether companies like Luminai can prove that the category removes friction rather than just processing it faster. That is what would turn this from a hot funding story into a lasting healthcare story.

SPONSORED BY RŌG HEALTH

86% of Medtech Teams Have Claims Their Evidence Can’t Back Up

In our Q1 client study, that’s what we found — claims outpacing evidence by enough to create real exposure in investor due diligence, health system reviews, or partner conversations. Most teams don’t see it because nothing breaks until the room actually matters.

We recently worked with a company preparing for a $25M Series A raise. Three weeks out, we found a claims-evidence gap that would have surfaced in due diligence. They fixed it before it cost them.

If you’re heading into a raise, a launch, or a strategic conversation in the next 90 days, this is the window to find out. We’re accepting a small number of medtech teams now.

See if you qualify →

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about sponsorship opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

This week’s signal: neurovascular innovation and commercialization readiness are moving in parallel — with major acquisitions, fresh capital, and regulatory wins shaping who scales next.

8 things to watch this week:

1. 🧠 Stryker to Acquire Amplitude Vascular Systems

Stryker’s move into next-generation intravascular lithotripsy is a meaningful portfolio expansion in peripheral vascular, especially as calcified PAD remains a stubborn procedural challenge. For medtech leaders, this is another reminder that strategics are still willing to buy differentiated platforms that can slot cleanly into an existing commercial engine.

Endovascular Today

2. 💰 Gilead to acquire Tubulis in up to $5 billion deal to strengthen oncology pipeline

The size of the deal stands out, but so does the thesis: targeted delivery platforms still command premium strategic value when they bring credible clinical assets with them. Even for device operators, it is a useful signal that platform-plus-pipeline stories continue to attract real buyer urgency.

MedTech World

3. 🎯 86% of Medtech Teams Have Claims Their Evidence Can’t Back Up

In our Q1 client study, that’s what we found — claims outpacing evidence by enough to create real exposure in investor due diligence, health system reviews, or partner conversations. Most teams don’t see it because nothing breaks until the room actually matters.

We recently worked with a company preparing for a $25M Series A raise. Three weeks out, we found a claims-evidence gap that would have surfaced in due diligence. They fixed it before it cost them.

If you’re heading into a raise, a launch, or a strategic conversation in the next 90 days, this is the window to find out. We’re accepting a small number of medtech teams now.

→ See if you qualify

4. 🔬 Monteris Medical Secures $28 Million in Growth Equity to Accelerate Revenue and Innovation in Minimally Invasive Neurosurgery

Monteris is raising growth capital to expand its U.S. commercial footprint, push technology development, and deepen clinical research around NeuroBlate. That combination matters: investors are still backing companies that can pair procedural differentiation with evidence generation and a clear path to broader adoption across health systems.

PR Newswire

5. 🤖 Luminai Raises $38 million Series B to Scale Intelligence Across Health System Operations

AI stories are everywhere, but Luminai’s angle is operational infrastructure rather than headline-grabbing automation theater. That makes this one worth watching: health systems are increasingly buying tools that promise workflow lift, measurable labor leverage, and cleaner execution in the back half of care delivery.

PR Newswire

6. 😴 ProSomnus gets FDA nod for latest sleep apnea therapy device

ProSomnus’ FDA clearance for RPMO₂ adds physiologic monitoring to oral appliance therapy, pushing sleep apnea treatment toward a more data-rich, feedback-driven model. Strategically, that is the interesting part: devices that do not just treat, but also generate monitoring data, tend to create stronger clinical and commercial positioning.

MassDevice

7. 🏥 Dimer Health Raises $13.5 Million | Thesis Care Announces $45 Million Series A

Both raises point at the same pressure point: health systems still need capacity, especially in moments where labor-intensive clinical work creates bottlenecks. Dimer’s post-discharge model and Thesis Care’s AI-supported clinical teams both reflect where buyers are spending now — on tools that promise operational relief without pretending clinicians are optional.

Healthcare IT Today

8. 🧬 Miracell Secures U.S. FDA Clearance for SMART M-CELL, Advancing Regenerative Therapies

Miracell’s 510(k) clearance adds another data point to the broader regenerative medicine buildout, especially around systems that aim to preserve cell viability while making extraction and concentration more usable in practice. It is still an earlier signal than some of the stories above, but it is a category worth tracking as procedural regenerative applications continue to mature.

BioPharma APAC

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about sponsorship opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

Boston Scientific’s Watchman heart implant measures up to blood thinners in ACC trial

For years, Watchman has occupied a clear place in the atrial fibrillation treatment map. It was the device you talked about when blood thinners stopped looking like a clean long-term answer.

CHAMPION-AF suggests Boston Scientific wants to redraw that map.

The headline result was strong enough to invite that ambition. In data presented at ACC.26 and simultaneously published in the New England Journal of Medicine, Watchman FLX met non-inferiority against NOACs on a composite primary efficacy endpoint of cardiovascular death, stroke, and systemic embolism. On the primary safety endpoint — non-procedural bleeding — the device didn’t just clear the bar. It showed statistical superiority, with a combined rate of major and clinically relevant non-major bleeding of 15.1% versus 21.8% in the NOAC arm. Boston Scientific has said it plans to use the trial to pursue both an expanded label and a revised Medicare national coverage decision.

One other thing worth noting before getting to the market argument: this is structurally different from prior Watchman evidence. PROTECT-AF and PREVAIL compared the device against warfarin — a therapy the field had largely moved past. CHAMPION-AF is the first large randomized trial to put Watchman head-to-head against DOACs, in patients who were actually eligible for anticoagulation. That distinction matters for how much weight the result can carry.

On one level, this is a familiar medtech story: generate the evidence, widen the indication, grow the franchise.

But this one matters because it is really a story about where stroke prevention happens.

Drug-based prevention has always had one enormous advantage over device-based prevention: it fits the default logic of care. A prescription is easy to write, easy to scale, and easy to understand. A structural heart procedure is none of those things. It asks for specialist judgment, lab capacity, procedural confidence, and a reimbursement structure that makes the extra work worthwhile.

So when Boston Scientific pushes Watchman deeper into the market, it is not just asking whether the device works. It is asking whether the care pathway itself is ready to change.

That is a much bigger question.

Left atrial appendage closure is no longer an isolated niche. Boston Scientific has described Watchman as a major growth platform, and its broader structural heart messaging makes clear that the company sees this market as something to build outward, not simply defend.

The commercial logic is easy to see. If physicians and payers become more comfortable treating Watchman as an earlier option rather than a later fallback, Boston Scientific does not just sell more devices. It expands the category’s clinical perimeter.

That is where the trial starts to feel more consequential than a typical positive readout.

Because the real contest here is not device versus drug. It is routine versus exception.

Watchman has historically benefited from a simple narrative: some patients need an alternative to chronic anticoagulation. What Boston Scientific is now testing is whether that narrative can be broadened. Can an implant move from being the answer for selected patients to being a reasonable first conversation for many more of them?

That is a tougher leap than it sounds.

Physicians do not change habits because a company wants a larger market. They change habits when the evidence is persuasive, the workflow becomes manageable, and the economic logic stops fighting the clinical one. Even then, adoption tends to move unevenly. Leading centers go first. Everyone else waits to see whether the enthusiasm becomes routine practice.

And CHAMPION-AF, for all its upside, still leaves some room for hesitation. Ischemic stroke was numerically higher in the device arm — 3.2% versus 2.2% — a difference that was not statistically significant on a secondary endpoint, but one that the trial’s own investigators flagged as requiring longitudinal follow-up. The five-year data, not yet available, will be the more decisive read on that signal.

The trial also sits in a more complicated evidentiary landscape than its top-line results suggest. CLOSURE-AF, presented at AHA 2025, found that left atrial appendage occlusion failed to meet noninferiority against standard care in patients at high combined risk of stroke and bleeding — a population where the procedure has been most widely used. The NEJM editorial accompanying CHAMPION-AF cited that result directly, and several prominent cardiologists argued the negative trial raises the burden of proof for any new LAAC evidence. Boston Scientific’s data are more favorable, and in a meaningfully different patient population, but the field is not reading CHAMPION-AF in a vacuum.

None of that negates the result. But it does keep the conversation open.

Which is probably why this story performed so well in the first place.

It is not just a good-news clinical trial story. It is a market-shaping argument disguised as one.

Readers can feel the stakes immediately. If Watchman stays where it is today, Boston Scientific still has an important franchise. If the company succeeds in shifting physician behavior and payer confidence, then left atrial appendage closure begins to look less like a carveout and more like a reordering of the atrial fibrillation treatment stack.

That is the difference between a product win and a category win.

And this week, the market seems to have recognized that difference.

The question now is not whether Watchman generated positive data. It is whether Boston Scientific has finally assembled enough evidence to make a procedure compete with the default convenience of a pill.

SPONSORED

Your Commercial Story Will Get Tested.
The Question Is When.

You’ll spend years getting to clearance. You’ll spend weeks preparing the deck. Most teams never spend a day finding out whether their commercial story actually holds up from the outside.

That’s the gap the CLiF Pioneer Cohort closes — before a fundraise, a launch, or a partnership conversation where it’s too late to fix it.

Ten seats. Two rounds. Half the rate.

Claim your seat →

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about sponsorship opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

8 things to watch this week:

1. 💰 Whoop raises $575M, eyes IPO as health platform scales

Whoop’s latest raise and IPO ambitions signal continued investor appetite for consumer-driven health platforms—especially those positioning as longitudinal data engines rather than single-use devices. The question now: how far can wearables stretch into clinical relevance?

The Next Web

2. 🔐 Stryker contains cyberattack, begins system restoration

Stryker confirmed a cyberattack impacting systems, now contained as recovery begins. The bigger signal: medtech remains highly exposed to operational disruption—and cybersecurity is quickly becoming a board-level risk, not just an IT issue.

Cybersecurity Dive

3. 🎯 86% of Medtech Companies Have a Hidden Deal Risk

In our Q1 client study, we discovered that 86% of companies had claims that outpaced their evidence—enough to create real exposure in investor due diligence, health system reviews, or partner conversations. Most teams don’t see it because nothing breaks until the room actually matters. We recently caught this in a company preparing for a $25M Series A!

RŌG Health exists for this exact moment: to surface where your story doesn’t hold up before it costs you.

We’re working with a small group of medtech teams going through this now.
→ Learn more

Sponsored

4. 🫀 J&J’s Impella shows no patient benefit in major trials

New trial data found no meaningful patient benefit for Impella heart pumps, raising serious questions about clinical value versus widespread adoption. Expect ripple effects across cardiac device positioning and hospital purchasing scrutiny.

MedTech Dive

5. 🩺 Boston Scientific’s Watchman shows reduced reliance on blood thinners

New data suggests Watchman may help patients avoid long-term blood thinner use, reinforcing its value proposition in atrial fibrillation care. It’s another step toward device-led alternatives to chronic drug therapy.

Fierce Biotech

6. 🧠 Philips wins FDA clearance for next-gen imaging system

Philips secured FDA clearance for a new imaging platform, continuing its push to modernize diagnostic workflows. Imaging remains a battleground for incremental innovation with outsized operational impact.

Yahoo Finance

7. ⚡ GE Healthcare’s Photonova Spectra clearance signals imaging push

GE Healthcare’s latest FDA clearance adds to its imaging portfolio, signaling continued investment in advanced diagnostics. The broader play: tighter integration of imaging into data-driven care pathways.

Simply Wall St

8. 🧪 eMed raises $200M at $2B+ valuation

eMed’s $200M raise highlights sustained investor interest in decentralized diagnostics and digital care models. The question is whether these platforms can convert pandemic-era momentum into durable infrastructure.

PR Newswire

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about sponsorship opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

Medtronic wins FDA clearance for robot in cranial, ENT surgeries

Medtronic’s latest FDA clearance extends its Stealth AXiS platform into cranial and ENT procedures — but the real signal isn’t the new indications. It’s what those indications suggest about where surgical robotics goes when the obvious opportunities are already taken.

For the past decade, robotics scaled through high-volume, standardized procedures where utilization was predictable and the economics were clear. That playbook doesn’t translate cleanly here.

Cranial surgery is inherently limited in volume and highly variable. Surgeons already operate with established navigation systems that deliver sub-millimeter precision. Robotics in this setting isn’t filling a gap — it’s competing against workflows that already work.

ENT complicates the picture in the opposite direction. Sinus procedures are common and repeatable, but they’re also fast and efficient, built around endoscopic techniques that don’t obviously require robotic augmentation. Medtronic’s system adds navigation and visualization at the skull base, but the question is whether that incremental capability justifies introducing a new layer of technology into already optimized cases.

That tension — low-volume precision on one side, high-volume efficiency on the other — is where this expansion lives.

Medtronic’s answer is not procedural. It’s architectural.

Stealth AXiS combines planning, navigation, imaging, and robotics into a single platform, designed to be deployed across spine, cranial, and ENT rather than anchored in any one category. The underlying assumption is that no single specialty needs to carry the system — enough adjacent ones, layered together, can.

There’s precedent for both outcomes.

Robotic platforms that scaled successfully did so by locking in high-volume use cases first, then expanding outward. But expansion into lower-volume or highly specialized segments has historically been uneven, often remaining concentrated in large academic centers rather than translating into broad, repeatable use.

That’s the fault line here.

If this model works, robotics becomes less about individual procedures and more about owning the surgical workflow — a multi-specialty platform that integrates planning, navigation, and execution across service lines. If it doesn’t, it starts to look like a system extending into adjacent indications without a clear driver of consistent utilization.

The technology itself isn’t the constraint. Stealth AXiS integrates real-time imaging, navigation, and robotic guidance — the pieces are there.

The constraint is behavioral.

Hospitals need enough case volume to justify capital investment. Surgeons need repetition to change how they operate. Cranial doesn’t naturally provide the first. ENT may not demand the second.

FDA clearance opens the door. What matters now is whether enough procedures actually move through it — because in this segment, systems don’t gradually become routine. They either earn consistent use, or they remain optional.

Do you see robotics gaining real traction in cranial or ENT — or staying concentrated in major centers?

SPONSORED

Before Your Commercial Story Gets Tested —
Test It Yourself

Most teams don’t pressure-test their commercial story ahead of time. They only find out where it breaks when it actually matters — in front of an investor, a health system, or a potential partner.

RŌG Health’s CLIF Analysis was built for exactly this. Before the room. Before it matters.

RŌG Health is opening ten seats to a limited cohort for medtech and medical device companies at serious commercial inflection points. Two rounds of external analysis. Half the standard rate. Ten seats. First come, first served.

→ Learn more and register today

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about sponsorship opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

8 things to watch this week:

1. 🤖 Medtronic pushes robotics into cranial & ENT procedures

Medtronic’s latest FDA clearance expands its robotic platform into cranial and ENT surgeries, signaling a continued push toward multi-specialty dominance. The bigger story: robotics is shifting from single-use cases to scalable surgical ecosystems.

MedTech Dive

2. 🎯 Before Your Commercial Story Gets Tested — Test It Yourself.

Most teams don’t pressure-test their commercial story ahead of time. They only find out where it breaks when it actually matters — in front of an investor, a health system, or a potential partner.

The CLIF Analysis was built for exactly this. Before the room. Before it matters.

RŌG Health is opening ten seats to a limited cohort for medtech and medical device companies at serious commercial inflection points. Two rounds of external analysis. Half the standard rate. Ten seats. First come, first served.

Learn more and register today →

Sponsored

3. 🧠 At-home neuromodulation gains traction post-FDA approval

With new funding following FDA approval, Neurolief is pushing neuromodulation into the home — a meaningful step toward decentralizing mental health treatment. This reinforces a broader shift: high-acuity therapies moving outside traditional care settings.

BioSpace

4. 💧 Boston Scientific secures FDA clearance for fluid management system

Boston Scientific’s new system targets improved visualization and pressure control during ureteroscopy procedures. While incremental, it reflects continued investment in procedural efficiency and outcomes in high-volume specialties.

Boston Scientific

5. 🧬 BioLargo subsidiary Clyra Medical accelerates toward product launches

Clyra Medical is moving closer to commercialization with its wound care platform, highlighting continued momentum in infection control and advanced healing technologies. The broader signal: niche clinical categories are becoming serious growth markets.

Seeking Alpha

🧠 Butterfly Network wins FDA clearance for AI-powered ultrasound tool

Butterfly’s newly cleared AI ultrasound can estimate gestational age in minutes without specialist interpretation, dramatically expanding access to prenatal imaging. The bigger signal: AI is starting to compress both expertise and infrastructure requirements in frontline care.

Reuters

7. 💻 VITL raises $7.5M to scale healthcare software platform

VITL’s Series A highlights ongoing investor appetite for infrastructure-layer healthcare software. The focus is clear: enabling interoperability and data flow across fragmented systems.

N24

❤️ JenaValve wins FDA approval for first-in-class aortic regurgitation valve

JenaValve’s FDA approval marks the first transcatheter device specifically designed for aortic regurgitation — a historically underserved condition. Beyond the clinical milestone, it signals renewed momentum in structural heart innovation following increased regulatory and antitrust scrutiny.

MedTech Dive

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about sponsorship opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

8 things to watch this week:

1. 🧬 Abbott completes Exact Sciences acquisition

Abbott is doubling down on diagnostics as a growth engine, signaling continued convergence between testing, monitoring, and intervention. This move strengthens its position across the full care pathway.

MassDevice

2. 🩻 GE HealthCare’s Photonova Spectra photon-counting CT receives FDA clearance

Photon-counting CT has long been viewed as the next frontier in imaging, and this clearance pushes it into real-world deployment. Expect competitive acceleration in advanced imaging platforms.

BusinessWire

3. 🔎 Before You Raise, Launch, or Scale — Know If You’re Actually Ready

Medical device companies rarely fail because the technology doesn’t work.
They fail because commercialization, reimbursement, and adoption strategy weren’t aligned early enough. RŌG Health helps medtech leaders assess whether their company is truly ready for key milestones such as FDA clearance, fundraising, and market launch.

Take our 1-minute readiness check to see where your strategy stands — and discover the engagement path designed for your stage. →

Sponsored

4. ⌚ FDA clears Mode Sensors fluid monitoring wearable

Continuous fluid monitoring via wearable sensors opens new pathways for managing chronic conditions outside the hospital. This is another step toward clinically relevant, always-on patient monitoring.

MSN

5. 💉 Embecta: $150 Million Acquisition Of Owen Mumford To Expand Drug Delivery Platform Capabilities

Embecta is expanding beyond insulin delivery into a broader drug delivery platform, signaling a push toward owning more of the therapeutic delivery stack.

Pulse2

6. 🏭 Resonetics completes the acquisition of Resolution Medical

This acquisition strengthens Resonetics’ position as an end-to-end manufacturing partner, reflecting growing demand for vertically integrated medtech development and production.

PR Newswire

7. 📊 Report says US cardiovascular devices market to reach $41.29 billion by 2032

The projected growth underscores sustained demand in cardiovascular care, reinforcing why strategics continue to prioritize investment and acquisition in this category.

DAIC

8. 🤝 Ibex and HNL Lab partner on prostate cancer diagnostics

AI-driven diagnostics continue to expand into clinical workflows, with partnerships like this accelerating adoption in pathology and cancer detection.

Medical Device Network

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about sponsorship opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

Also, a quick thank you to Kelvyn Cullimore, President & CEO of BioUtah (former CEO at Dynatronics), for hosting an outstanding life sciences event in Salt Lake City last week and including us in the conversation. The energy around Utah’s medtech ecosystem was unmistakable.

LSI USA ‘26 Emerging Medtech Conference begins today in Dana Point, CA, USA.

8 things to watch this week:

1. 🧠 Medtronic Expands Neurovascular Portfolio With Scientia Acquisition

Medtronic is expanding its neurovascular capabilities through the acquisition of Scientia Vascular, signaling continued consolidation around stroke and neurovascular intervention technologies. The move reinforces how strategic acquisitions remain one of the fastest paths for large strategics to strengthen highly specialized portfolios.

Today’s Medical Developments

2. 💰 Vitestro Raises $70M to Advance Autonomous Blood Draw Technology

Vitestro secured $70 million to accelerate development of its autonomous blood-draw platform, aiming to address workforce shortages and streamline diagnostics workflows. Automation at the point of care is becoming one of the most compelling investment themes across health systems.

Ventureburn

3. 🧠 xCATH Secures $30M Series C to Improve Global Outcomes in Neurovascular Care

xCATH raised $30 million to expand its robotic catheter technology designed for remote stroke intervention. The funding reflects growing interest in robotic endovascular procedures that could enable specialists to treat patients across geographic boundaries.

Zawya

4. 🔎 Before You Raise, Launch, or Scale — Know If You’re Actually Ready

Medical device companies rarely fail because the technology doesn’t work.
They fail because commercialization, reimbursement, and adoption strategy weren’t aligned early enough. RŌG Health helps medtech leaders assess whether their company is truly ready for key milestones such as FDA clearance, fundraising, and market launch.

Take our 1-minute readiness check to see where your strategy stands — and discover the engagement path designed for your stage. →

Sponsored

5. 🧾 QT Imaging Achieves Major Reimbursement Milestone With AMA Category III CPT Code for 3D Breast Imaging

QT Imaging secured a Category III CPT code for its 3D breast imaging technology — an important step toward broader reimbursement and clinical adoption. For emerging device companies, coding milestones often mark the transition from technical validation to scalable commercialization.

Nasdaq

6. 👁️ FDA Approves TECNIS PureSee IOL for Cataract Patients

Johnson & Johnson’s TECNIS PureSee intraocular lens received FDA approval, adding another option in the rapidly evolving premium cataract lens market. Incremental optical performance improvements continue to drive competition in one of ophthalmology’s most commercially mature segments.

Eyes On Eyecare

7. 🖥️ GE Healthcare Imaging Viewer Granted FDA Clearance

GE Healthcare received FDA clearance for a new imaging viewer designed to enhance visualization and workflow for clinicians reviewing diagnostic scans. Software-enabled imaging tools are becoming increasingly central to clinical decision-making and hospital efficiency.

ITN Online

8. ⚖️ FDA Finalizes Guidance on Weight-Loss Devices

The FDA finalized guidance outlining regulatory expectations for weight-loss devices, providing greater clarity for developers navigating obesity-related indications. With the rapid growth of GLP-1 drugs, the device side of metabolic health is likely to evolve quickly alongside pharmaceutical treatments.

RAPS

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about sponsorship opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

8 things to watch this week:

1. 💰 Danaher Announces Acquisition of Masimo Corporation in $9.9B Diagnostics Deal

Diagnostics consolidation continues as Danaher moves to acquire Masimo in a $9.9B deal, bringing patient monitoring technology into one of the largest life sciences portfolios in the world. The move signals how strategic diagnostics platforms have become as healthcare shifts toward data-driven decision making.

The Healthcare Technology Report

2. 🧬 Agilent to Acquire Biocare Medical, a Global Leader in Clinical and Research Pathology Solutions

Agilent plans to acquire Biocare Medical, expanding its capabilities in pathology diagnostics and research reagents. As biomarker-driven medicine grows, companies across the diagnostics stack are strengthening their ability to support advanced tissue analysis and clinical research.

BusinessWire

3. 🤖 Philips Advances Cardiac MR with FDA Clearance for SmartHeart AI

Philips received FDA clearance for SmartHeart AI, designed to streamline cardiac MRI workflows and accelerate image analysis. AI-enabled imaging continues gaining traction with regulators as providers look to increase throughput without sacrificing diagnostic accuracy.

Medical Device Network

4. 🔎 Before You Raise, Launch, or Scale — Know If You're Actually Ready

Medical device companies rarely fail because the technology doesn’t work.
They fail because critical commercialization decisions happen out of sequence.

RŌG Health helps medtech leaders pressure-test commercial readiness before capital, credibility, and time are put at risk.

Take our two minute readiness check →

5. 🦷 First-Ever Dental-Dedicated MRI Validated in Clinical Trial and Cleared by FDA for Advanced Soft Tissue Diagnostics

A dental-dedicated MRI system has been validated in clinical trials and cleared by the FDA, opening the door to improved soft-tissue imaging in oral and dental care. The approval highlights how specialized imaging systems are expanding diagnostic capabilities beyond traditional hospital environments.

BioSpace

6. 🌏 Baird Medical Accelerates U.S. Expansion

Baird Medical announced plans to accelerate its expansion into the U.S. market, reflecting continued global interest in American healthcare innovation and commercialization opportunities. International medtech companies increasingly view the U.S. as a critical market for scaling advanced devices.

Yahoo Finance

7. 🧪 Science Corp Raises $230M in Series C Round

Science Corp secured $230M in Series C funding, one of the larger venture rounds in the sector so far this year. The raise signals continued investor appetite for breakthrough medical technologies even as the broader venture market remains selective.

Medical Buyer

8. 🌐 Samsung Medison and HistoSonics Partner to Expand from Diagnostic Imaging to Therapeutic Ultrasound

Samsung Medison and HistoSonics announced a partnership to integrate histotripsy technology with diagnostic ultrasound, signaling a broader industry trend toward combining imaging with non-invasive therapeutic platforms. The collaboration reflects growing interest in technologies that blur the line between diagnosis and treatment.

Asiae

Bonus! Utah Life Sciences Event This Week

The BIO Utah Entrepreneur & Investor Life Sciences Summit takes place this week March 12–13 in Salt Lake City, bringing together founders, investors, and strategics focused on building the region’s next generation of medtech and biotech companies.

If you’re attending, let them know you heard about it in The Pathway.

Learn more →

Have an event to promote? Put it in front of 35,000 med-device leaders who read The Pathway each week. Contact us to learn more about sponsorship opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about sponsorship opportunities.

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

If you’d like to learn more about Afu, his life, or still contribute to the campaign, you can revisit last week’s newsletter here.

8 things to watch this week:

1. 💉 Abbott Wins FDA Approval for Updated Heart Failure Monitoring Device

Abbott secured FDA approval for its updated heart failure monitoring technology, reinforcing the strategic value of longitudinal patient data inside device ecosystems. For device leaders, this is another signal that remote monitoring + regulatory expansion is now a durable competitive moat.

MedTech Dive

2. 🧠 Radiology AI Firm Asks FDA to Exempt Certain Devices from Premarket Review

A radiology AI company is pushing for certain imaging tools to be exempt from FDA premarket review. If successful, this could meaningfully alter time-to-market assumptions for AI-enabled diagnostics — and shift capital allocation models across the imaging category.

Radiology Business

3. 💰 4DMedical Secures More Than $100M in Funding

4DMedical raised over $100M, underscoring investor appetite for advanced pulmonary imaging and functional lung diagnostics. Large rounds are increasingly consolidating category leaders early — raising the bar for competitors on both clinical validation and commercial scale.

MPO Magazine

4. 🔎 Commercial Strategy for Medical Device Leaders by RŌG Health

Medical device companies don’t struggle because they can’t build.
They struggle when commercialization, reimbursement, adoption, and capital strategy aren’t aligned.

RŌG Health helps device and medtech leaders pressure-test commercial readiness before major milestones — fundraising, FDA clearance, market expansion, or strategic partnerships.

We clarify the story, surface risk, and sharpen positioning — before execution capital is deployed. Strategic clarity for companies building in regulated markets.

Learn more about RŌG Health →

5. 📊 Tandem Bests $1B in Worldwide Sales

Tandem Diabetes Care surpassed $1B in global sales — a major milestone in the insulin pump category. Scale in chronic disease management remains one of the most defensible revenue models in med device when product iteration and ecosystem integration are tight.

San Diego Business Journal

6. 💵 Salma Health Raises $80M Series A

Salma Health closed an $80M Series A, signaling continued investor confidence in care platform infrastructure plays. Even adjacent digital health models are now raising capital with stronger expectations around measurable outcomes and pathway integration.

Pulse 2.0

7. 🧪 Theradep and DSM-Firmenich Announce Strategic Partnership to Advance Next-Gen Bio-Surface Technologies

Theradep and DSM-Firmenich announced a strategic partnership to accelerate bio-surface technologies. Surface science continues to be an under-discussed differentiator in implantables and device durability — especially as infection prevention and material performance remain core hospital concerns.

Gainesville Press Release

8. 🏥 Daffodil Health Raises $16.3M Series A; Synchrony Medical Secures $5M Funding

Two funding rounds in care enablement and medical technology signal continued activity in early-stage health IT and device infrastructure. Capital is flowing — but increasingly toward companies with clearer clinical integration strategies.

Healthcare IT Today

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about sponsorship opportunities.

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

Our thoughts and prayers are with his family and loved ones during this difficult time.

You can learn more about Afu’s story here. His family has established a GoFundMe to help ease the financial strain of the past four years. If you feel moved to support them, you can contribute here:
https://www.gofundme.com/f/help-afu-fiefia-overcome-cancers-return

8 things to watch this week:

1. 🧪 Haemonetics Receives FDA Clearance for NexSys PCS with Persona Plus

FDA clearance for Persona Plus technology inside Haemonetics’ plasma platform reinforces a broader shift: operational AI embedded into revenue-generating systems. Workflow optimization is now a competitive differentiator — not a feature add.

PR Newswire

2. 🏥 FDA Approves Allurion’s PMA Application

Allurion secures PMA approval — the FDA’s highest regulatory bar. In a disciplined capital market, PMA-backed platforms carry stronger acquisition credibility and pricing leverage.

Medical Device Network

3. 🤖 Medtronic Moves to Acquire CathWorks to Expand AI-Driven Coronary Diagnostics

Medtronic continues building AI depth through acquisition rather than internal experimentation. Expect more strategics to buy validated, workflow-integrated algorithms instead of building from scratch.

The Healthcare Technology Report

4. 🔎 Commercial Strategy for Medical Device Leaders by RŌG Health

Medical device companies don’t struggle because they can’t build.
They struggle when commercialization, reimbursement, adoption, and capital strategy aren’t aligned.

RŌG Health helps device and medtech leaders pressure-test commercial readiness before major milestones — fundraising, FDA clearance, market expansion, or strategic partnerships.

We clarify the story, surface risk, and sharpen positioning — before execution capital is deployed. Strategic clarity for companies building in regulated markets.

Learn more about RŌG Health →

5. 🔬 Quantum Surgical Announces Acquisition of NeuWave

Quantum Surgical expands its robotics footprint through NeuWave’s ablation technology. Platform adjacency remains the dominant M&A strategy — deepen the ecosystem, control more of the procedure.

Yahoo Finance

6. 🏛 Bloomberg Reports Potential Major Asset Sale by Johnson & Johnson

J&J is reportedly exploring a major asset sale as portfolio optimization continues post-spinoff. Expect sharper focus, fewer middle-tier assets, and more aggressive capital allocation moves from large-cap medtech.

MSN / Bloomberg

7. 🛡 Censinet Unveils Censinet GRC AI and Platform Innovations at ViVE 2026

Censinet introduces AI-driven governance, risk, and compliance tooling. As devices become software-enabled and cloud-connected, cybersecurity and vendor risk oversight are increasingly board-level priorities.

Citizen Times

8. 💰 Handl Health Secures $14M Series A to Reform Healthcare Access and Affordability

Handl Health raises capital to expand healthcare pricing and claims intelligence. Employer and payer cost pressure continues shaping reimbursement dynamics — and ultimately, med device margin structures.

PR Newswire

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about sponsorship opportunities.

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

If there’s a theme emerging this week, it’s strategic positioning — large-cap portfolio moves, AI infrastructure bets, and distribution partnerships all reinforcing that commercialization discipline is separating momentum from noise.

8 things to watch this week:

1. 💰 Danaher closes nearly $10B deal for Masimo’s consumer unit

Danaher has closed its nearly $10B acquisition of Masimo’s consumer business, continuing its portfolio refinement strategy. For device leaders, the signal is clear: strategic buyers remain active, but capital is flowing toward focused, thesis-driven assets.

Reuters

2. 🧠 Before You Execute, Pressure-Test the Commercial Story

Most medtech missteps don’t come from bad execution.
They come from acting on assumptions that were never examined.

The CLIF Analysis is a fast, external review of how your company presents itself—based on your pitch deck, website, and public materials. We assess where the story is clear, where it relies on assumptions, and where gaps may create downstream risk.

Not a roadmap. Not execution.
A structured reality check to help leaders decide whether deeper readiness work is warranted.

Explore the CLIF Analysis →

3. 🤖 GE HealthCare and BARDA launch $35M AI ultrasound collaboration

GE HealthCare is partnering with BARDA on a $35M AI-enabled ultrasound initiative to strengthen diagnostic readiness. Public-private AI infrastructure investments continue to expand, signaling durable federal support for embedded clinical AI.

MassDevice

4. 📈 Medtronic earnings: Can new products fuel growth?

Medtronic’s latest earnings raise a familiar question: can pipeline innovation reaccelerate growth? For established device companies, operational stability is no longer enough — product velocity and category expansion remain central to valuation.

Investing.com

5. 🤝 How CathWorks leaned on its partner Medtronic to succeed

CathWorks credits its partnership with Medtronic as a key lever in scaling adoption. Strategic channel alignment continues to be one of the clearest paths from regulatory clearance to meaningful market penetration.

Medical Design & Outsourcing

6. 💵 Nanochon targets $20M Series A after strong start to 2026

Nanochon is pursuing a $20M Series A following early traction in orthopedics. Venture capital in med device remains selective, with investors favoring companies that combine technical differentiation with credible commercialization strategy.

VoxelMatters

7. 🏠 Owlet partners with PromptCare to expand BabySat pulse oximeter footprint

Owlet has partnered with PromptCare to broaden distribution of its BabySat pulse oximeter. As care continues shifting beyond hospital walls, HME channel strategy is becoming increasingly central to remote monitoring growth.

HME News

8. 🌍 Median Technologies establishes distribution partnership

Median Technologies announced a new distribution partnership to expand its commercial reach. For software-enabled medtech companies, distribution infrastructure often determines how quickly regulatory wins translate into revenue.

Yahoo Finance

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about sponsorship opportunities.

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

8 things to watch this week:

1. ⚖️ Medtronic ordered to pay $382M in anticompetitive surgical device lawsuit

A federal jury found Medtronic liable for anticompetitive conduct tied to its surgical device business, awarding $382M in damages. The ruling underscores growing scrutiny around pricing strategy, bundling, and channel control — risks that often remain invisible until they become expensive.

Medical Device Network

2. 🧠 Before You Execute, Pressure-Test the Commercial Story

RŌG Health works with medtech leaders to surface hidden assumptions that derail commercialization — often long before execution makes those risks costly.

Our proprietary Commercial Launch Impact Framework — or CLIF Analysis — is one way we do that: a fast, external review of your pitch, website, and public materials to identify where the story is clear, where it relies on assumptions, and where gaps could create downstream risk with customers, partners, or investors.

Explore the CLIF Analysis →

3. 🧠 FDA clears Median Technologies’ lung nodule evaluation software

The FDA has cleared Median’s AI-driven software for lung nodule assessment, reinforcing momentum in regulated imaging analytics. As AI moves deeper into diagnostics, regulatory readiness is increasingly a competitive advantage — not just a hurdle.

Medical Device Network

4. 🦠 UV-Smart receives FDA 510(k) clearance for TEE probe disinfection system

UV-Smart’s D60 system secured FDA clearance for automated TEE probe disinfection, addressing infection control in high-risk procedures. Products that reduce clinical risk while improving workflow efficiency continue to resonate with hospital buyers.

Business Wire

5. 🤝 Axena Health and Mayo Clinic expand pelvic health collaboration

Axena Health and Mayo Clinic are expanding their collaboration to advance digital pelvic health solutions. Strategic provider partnerships remain one of the clearest ways to validate emerging categories and accelerate adoption.

MPO

Share The Pathway

6. 🧾 Medical simulation market projected to reach $7.23B by 2030

The global medical simulation market is expected to see steady growth through 2030, driven by clinician training demands and workforce shortages. Simulation is increasingly viewed as operational infrastructure, not optional tooling.

PR Newswire / MarketsandMarkets

7. 🤖 As AI enters the OR, reports surface of surgical errors and misidentification

New reports detail cases where AI-assisted surgical tools contributed to misidentified anatomy and procedural errors. As adoption accelerates, governance, validation, and accountability are becoming as important as performance claims.

OODA Loop

8. 🌍 The medical device industry grapples with tariffs and supply chain pressure

Tariffs and trade uncertainty are forcing device manufacturers to reassess sourcing, pricing, and margin strategy. For leadership teams, supply chain resilience is now a core strategic concern — not just an operational one.

Medical Economics

Bonus story:

🇺🇸 PulseNmore builds U.S. momentum following FDA clearance

PulseNmore is expanding U.S. commercial engagement following FDA clearance for its remote ultrasound technology. It’s a reminder that regulatory wins only matter when paired with disciplined go-to-market execution.

PR Newswire

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about sponsorship opportunities.

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

8 things to watch this week:

1. 🔍 Abbott–Exact Sciences deal to be reviewed by Australian antitrust regulator

Australia’s competition watchdog will review Abbott’s proposed acquisition of Exact Sciences, underscoring how cross-border regulatory risk is now a standard consideration for large diagnostics and device transactions. For strategics, global antitrust scrutiny is no longer a post-signing afterthought.

MLex

2. 🫀 Medtronic reports positive PENTITUDE data in STS patients

Medtronic shared encouraging clinical data supporting its PENTITUDE platform in high-risk surgical patients, reinforcing its pipeline momentum. Strong outcomes data remains one of the most durable competitive moats in today’s crowded device categories.

MassDevice

3. 🧪 Velosity opens precision development center to accelerate device launches

Velosity’s new development center is designed to shorten timelines from concept to commercialization, reflecting growing demand for outsourced, high-speed product development. Device leaders continue to invest in infrastructure that de-risks and accelerates innovation.

Today’s Medical Developments

4. 🧠 Before You Execute, Pressure-Test the Commercial Story

Most medtech missteps don’t come from bad execution.
They come from acting on assumptions that were never examined.

The CLIF Analysis is a fast, external review of how your company presents itself—based on your pitch deck, website, and public materials. We assess where the story is clear, where it relies on assumptions, and where gaps may create downstream risk.

Not a roadmap. Not execution.
A structured reality check to help leaders decide whether deeper readiness work is warranted.

Explore the CLIF Analysis →

5. 🛌 REMSleep receives Medicare PDAC coding approval for DeltaWave portfolio

REMSleep secured PDAC approval across its DeltaWave sleep diagnostics lineup, a key reimbursement milestone. Coding clarity remains a major unlock for adoption, especially in home-based and diagnostic technologies.

The Post and Courier (Berkeley Independent)

Share The Pathway

6. 📜 Understanding CMS’s new accreditation rules tied to competitive bidding

CMS has updated accreditation requirements that directly affect participation in competitive bidding programs. For device and DME companies, compliance strategy is increasingly inseparable from commercial strategy.

HomeCare Magazine

7. 🧬 Abbott resets nutrition business while expanding diagnostics and devices

Abbott is recalibrating its nutrition strategy while doubling down on diagnostics and medical devices. The move highlights how large med tech players are actively reshaping portfolios toward higher-growth, higher-margin segments.

Simply Wall Street

8. 💰 Four notable health tech funding rounds in January

January funding activity shows continued investor interest in select health tech and device-adjacent platforms, even amid a cautious capital environment. For operators, funding trends remain a useful proxy for where competition and partnerships may emerge next.

MedCity News

Bonus story:

🤝 Drive Medical agrees to acquire Compass Health Brands

Drive Medical’s acquisition of Compass Health Brands signals ongoing consolidation in durable medical equipment and home care. Scale, distribution, and product breadth continue to drive dealmaking in this segment.

THIIS

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about sponsorship opportunities.

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

8 things to watch this week:

1. 🧠 What Elekta (OM:EKTA B)’s FDA Nod for AI CT-Linac and New Vice Chair Means For Shareholders

Elekta picked up FDA 510(k) clearance for its AI-enhanced Evo CT-Linac, adding a U.S. commercial catalyst for CT-guided radiation workflows. Pairing that with a board governance update signals a company trying to translate innovation wins into steadier execution and credibility with providers and investors.

Simply Wall St

2. 📈 ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission

ImmunityBio shares jumped after the company said FDA discussions aligned on the path to resubmit ANKTIVA’s sBLA in papillary NMIBC. For device + diagnostics leaders, it’s another reminder that regulatory clarity (even before approval) can rapidly change competitive timelines and partnering leverage around therapy-adjacent tech.

Zacks Investment Research

3. ❤️ Medtronic Advances Cardiology And Diabetes Portfolio With New Approvals And Investment

Medtronic stacked a structural-heart investment (Anteris), EU approval + initial U.S. clinical use for Affera’s Sphere-360 PFA catheter, and FDA clearance for MiniMed Go. Net: continued convergence of electrophysiology, structural heart, and connected diabetes—two of the most competitive “platform” battlegrounds in medtech.

Simply Wall St

4. 🧩 Resonetics acquires Med Ally pulse generator lead manufacturing assets

Resonetics is expanding its bioelectronics/neuromodulation footprint by bringing pulse generator + lead manufacturing assets and know-how in-house. Strategically, it’s about offering more of the AIMD stack—reducing supply chain risk, tightening process IP control, and making Resonetics more “one-stop” for customers pushing toward integrated implant platforms.

The Post and Courier (Berkeley Independent)

5. 🧠 Commercial Decisions Are Far Too Costly for Guessing

Launching, partnering, or fundraising without a defensible view of commercial readiness is one of the fastest ways to destroy value in medtech. RŌG Health works upstream of execution to help leadership teams identify what’s blocking progress and decide, with confidence, what matters next.

Not an agency. Not execution. Decision-grade clarity at inflection points.

Contact RŌG for more info →

Share The Pathway

6.🤝 Strategic partnership created to support early medical device innovation

Medical Murray and Merge formed a partnership aimed at speeding early-stage innovation (design/prototyping) while creating a cleaner handoff into regulated development and cleanroom manufacturing. This is the playbook we’ll keep seeing: “front-end” innovation studios pairing with downstream manufacturing specialists to shrink time-to-first-real-build without overburdening teams with full QMS too early.

Today’s Medical Developments

7. 🏥 What ACCESS, TEMPO could foreshadow for commercial plans: Angle Health CEO

Angle Health’s CEO argues CMS’s ACCESS model and FDA’s TEMPO pilot could speed real-world evidence generation and shorten the time between adoption, proof, and payment—signals that would ripple into commercial plan expectations. Translation for digital health + device companies: evidence standards may get clearer (and faster), but the bar for ROI and outcomes won’t get lower.

Becker’s Payer Issues

8. 🦾 Intuitive’s da Vinci 5 Secures FDA Cardiac Clearance

Intuitive says FDA cleared da Vinci 5 for use in several cardiac procedures (with a measured rollout), expanding one of the most strategically valuable procedure categories in robotics. The near-term story is training and controlled adoption; the longer-term story is how quickly competitors can answer as cardiac becomes a new proving ground for premium robotic platforms.

MD+DI Online

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items. Interested in becoming a sponsor? Contact us.

If there’s a throughline this week, it’s scale—AI platforms pushing into healthcare, strategics expanding portfolios, and smaller teams advancing toward pivotal trials.

8 things to watch this week:

1. 🧠 Anthropic expands into healthcare a week after OpenAI launched a similar product

Anthropic has launched Claude for Healthcare, a HIPAA-ready platform that embeds its AI models into clinical, payer, consumer health, and life sciences workflows to rival OpenAI’s healthcare push.

Business Insider

2. 🤝 ATEC and Theradaptive Enter Strategic Partnership for Breakthrough Regenerative Technology in Spinal Fusion

Alphatec (ATEC) and Theradaptive have formed a strategic partnership giving ATEC exclusive U.S. rights to commercialize Theradaptive’s OsteoAdapt osteoinductive bone graft for spinal fusion, which is built on the AMP2 platform and carries multiple FDA Breakthrough Device Designations. The deal combines upfront, milestone, and royalty payments and will support Theradaptive’s pivotal OASIS spinal fusion trial and manufacturing scale-up in a U.S. spine market exceeding $10 billion annually.

PR Newswire

3. 🤝 Boston Scientific Announces Agreement to Acquire Valencia Technologies Corporation

Boston Scientific has agreed to acquire Valencia Technologies and its FDA-approved, coin-sized eCoin tibial nerve stimulation implant, expanding the company’s urology portfolio for treating urge urinary incontinence in people with overactive bladder, with the deal expected to close in the first half of 2026 and have an immaterial impact on 2026 adjusted EPS.

Boston Scientific

4. 🧪 Before You Launch, Pressure-Test the Story

Strong clinical data doesn’t automatically translate to commercial traction. RŌG Health helps medical device teams identify where messaging, market fit, and execution plans break down using their proprietary Commercial Readiness Diagnostic (CRD).

Contact RŌG for more info →

Share The Pathway

5. 🛡️ FDA Clears At-Home Neuromodulation Device for Major Depressive Disorder

The FDA has cleared ProlivRx, a wearable at-home neuromodulation headset that delivers external occipital and trigeminal nerve stimulation as an adjunct treatment for adults with major depressive disorder who have not responded adequately to at least one antidepressant.

EMPR

6. 🛡️ Medtronic Diabetes announces FDA clearance for MiniMed Go™ Smart MDI system featuring Instinct sensor made by Abbott

Medtronic has received FDA 510(k) clearance for its MiniMed Go smart MDI system, which connects the InPen smart insulin pen with Abbott’s Instinct CGM sensor via the MiniMed Go app to provide real-time dosing guidance and glucose insights for insulin-requiring people with type 1 and type 2 diabetes.

PR Newswire

7. 🤝 StimLabs® and Geistlich Expand Their Partnership with a New Product Anticipated Q2 2026

StimLabs and Geistlich are expanding their regenerative medicine partnership to co-develop and launch a new novel wound care product expected in Q2 2026, building on their existing Derma-Gide® distribution agreement and combined scientific and commercial strengths.

PR Newswire

8. 📈 Nanochon closes $4.1M Seed Prime II Funding Round

Nanochon has closed an oversubscribed $4.1 million Seed Prime II round led by cultivate(MD), bringing its total funding to $11.3 million to advance its Chondrograft knee cartilage implant through first-in-human trials and toward a future pivotal study.

PR Newswire

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.
If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items. Interested in becoming a sponsor? Contact us.